Optimal timing of surgery for gastric cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis

Table 1 Basic characteristics of included studies

Author	Year	Country	Study design	Time intervals and Sample size	stage	NCT	endpoint	NOS^a
Liu et al.	2018	China	R	<4weeks: 111 4-6weeks: 48 >6weeks: 17	cT2-4, N0-3	SOX; XELOX	pCR; OS; DFS	7
Wu et al.	2019	China	R	<=4weeks: 70 5-6weeks: 103 >6weeks: 56	cT3/4, N+	SOX; XELOX	OS; DFS	7
Juan et al.	2020	Spain	R	<4weeks: 18 4-6weeks: 26 >6weeks: 16	cT2-4, N0-3	ECF; EOX; FLOT	DS; OS	7
Wang et al.	2020	China	R	<=21days: 49 22-28days: 93 29-35days: 108 36-42days:84 42-84days: 92	cT0-4, N0-3	SOX; XELOX	pCR; OS; DFS	7
Augustinas et al.	2021	Lithuania	R	<=30days:70 31-43days: 138 >=44days:72	cT2-T4, N+	FLOT; FP; ECX; EOX	mPR; OS; DFS	8

Abbreviations: R Retrospective study, SOX S-1 and oxaliplatin, XELOX Capecitabine and oxaliplatin, ECF Epirubicin, cisplatin and 5-FU, Eox Epirubicin, oxaliplatin and capecitabine, FLOT Docetaxel, oxaliplatin, leucovorin and 5-fluoracil, FP Fluoropyrimidine and platinum-based doublet, ECX Epirubicin, cisplatin, capecitabine
^aThe Newcastle Ottawa Quality Assessment Scale (NOS)

ISSN: 1477-7819